North America Pterygium Drug Market, By Disease Type (Progressive Pterygium and Atrophic Pterygium), Stages (Stage 2, Stage 3, Stage 1), Treatment (Artificial Tears/Topical Lubricants and Steroid Eye Drops), Formulation (Eye Drops, Eye Ointments, Others), Mode of Purchase (Prescription and Over the Counter (OTC)), Population Type (Geriatric and Adults), End-User (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Others), Country (U.S., Canada, Mexico) – Industry Trends and Forecast to 2029.
North America Pterygium Drug Market Analysis and Insights
Pterygium is a common ocular surface lesion that begins in the limbal conjunctiva within the palpebral fissure and progresses to the cornea. It is named after the Greek word pterygos, which means "wing". The lesion occurs more frequently at the nasal limbus than the temporal with a characteristic wing-like appearance. UV exposure is strongly linked to the occurrence of pterygia. Individuals having a history of elevated UV exposure and those living closer to the equator have a higher incidence (outdoor work). According to certain research, males have a somewhat higher incidence than females, which could be due to a higher rate of UV exposure.
It can cause redness, inflammation, and a change in the look of the eye; it can create astigmatism, which can cause blurry vision; and it can cause a whitish or pinkish growth covering the front of the eye. It could affect one or both eyes.
Pterygium is diagnosed using a microscope to examine the front components of the eye during a full eye examination and based on the appearance of tissue growth on the cornea from the white area of the eye.
Data Bridge Market Research analyses that the North America pterygium drug market will grow at a CAGR of 5.8% during the forecast period of 2022 to 2029.
2022 to 2029
2020 (Customizable to 2019 - 2015)
Revenue in USD Million, Volumes in Units, Pricing in USD
Disease Type (Progressive Pterygium and Atrophic Pterygium), Stages (Stage 2, Stage 3, Stage 1, Stage 4), Treatment (Artificial Tears/Topical Lubricants and Steroid Eye Drops.), Formulation (Eye Drops, Eye Ointments, Others), Mode of Purchase (Prescription and Over the Counter (OTC)), Population Type (Geriatric and Adults), End-User (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Others)
U.S., Canada, Mexico
Market Players Covered
Johnson & Johnson Services, Inc. (U.S.), Novartis AG (Switzerland), Akorn Operating Company LLC (U.S.), Bausch & Lomb Incorporated (Canada), AbbVie Inc. (U.S.), Prestige Consumer Healthcare Inc. (U.S.), Théa Laboratories (France), Wellona Pharma (India), Bayer AG (Germany), Zydus Group, Amneal Pharmaceuticals LLC (India), OASIS Medical (U.S.), Alcon (Switzerland), and Santen Pharmaceutical Co., Ltd. (Japan)
North America Pterygium Drug Market Dynamics
- Rise in incidences and prevalence of ophthalmic disorders
According to data published in the National Library of Medicine (National Center for Biotechnology Information) in 2021, the prevalence rates vary in different places. It is most abundant in Cameron's "pterygium belt," which runs between 37° north and south of the equator.
The most common causes of pterygium include long-term exposure to ultraviolet (UV) light from the sun (the most common cause) and eye irritation caused by hot, dry weather, wind, and dust. The affirmative factors state that this is the major driver for the North America pterygium drugs market.
- Rise in the geriatric population
With the growing geriatric population across the globe, the prevalence of ophthalmic diseases with severe ocular pain is also growing. According to data provided published in "Global Prevalence of Blindness and Distance and Near Vision Impairment in 2020: progress towards the Vision 2020 targets and what the future holds" by "The Association for Research in Vision and Ophthalmology" (ARVO) estimated 41.9 million people were blind.
With the growing population, the pressure on the healthcare system is increasing. The demand for care and services is rising to treat the problem of Ophthalmol disorder, including pterygium. Therefore, the increasing geriatric population is a great opportunity for the North America pterygium drug market.
Programs and initiatives to reduce the burden of eye diseases
The International agency to prevent blindness has launched several programs and initiatives with well-reputed NGOs and corporates to spread awareness and reduce the burden of eye diseases.
International Agency endorses our Children's Vision and an initiative co-founded by the Brien Holden Vision Institute and the Vision For Life fund (created by Essilor) for the Prevention of Blindness (IAPB)
- High cost of eye treatment and medication
The growing prevalence of various ophthalmic disorders has also increased the necessity for timely treatments. However, the treatments and proper medication for ophthalmology disorders are not very cheap. Recent studies show that the price of topical steroids price is increasing in the past few years. Even though some topical ophthalmic steroids like prednisolone are mildly cheap, other advanced medications and eye drops are still expensive.
The North America pterygium drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pterygium drug market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth.
Patient Epidemiology Analysis
The prevalence of ophthalmic disorders keeps showing a surge in growth due to the rise in chemical industries and pollution worldwide. Chemical burns and flash burns cause significant and severe ocular pain due to irritations over the eye surface.
According to data published in the National Library of Medicine (National Center for Biotechnology Information) in 2021, the prevalence rates vary in different places. It is most abundant in Cameron's "pterygium belt," which runs between 37° north and south of the equator. Pterygium prevalence has been reported to range from 0.3 to 29% worldwide.
The North America pterygium drug market also provides detailed market analysis for patient analysis, prognosis, and cures. Prevalence, incidence, mortality, and adherence are some data variables available in the report. Direct or indirect impact analysis of epidemiology to the market growth are analyzed to create a more robust and cohot multivariate statistical model for forecasting the market in the growth period.
Post-COVID-19 Impact on North America Pterygium Drug Market
COVID-19 has negatively affected the market. Lockdowns and isolations during pandemics complicate disease management and medication adherence. The lack of access to healthcare facilities for routine treatment and medication administration will further impact the market.
- In January 2022, Alcon announced the launch of Systane complete preservative-free lubricant eye drops in Europe. The product works to provide all-in-one dry eye relief with one drop by hydrating the layers of the tear film. This has helped the company to increase its product portfolio
North America Pterygium Drug Market Scope
The North America pterygium drug market is categorized into eight notable segments based on disease type, stages, treatment, and formulation, mode of purchase, population type, end-user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Progressive Pterygium
- Atrophic Pterygium
Based on disease, the North America pterygium drug market is segmented into progressive pterygium and atrophic pterygium.
- Stage 1
- Stage 2
- Stage 3
Based on stages, the North America pterygium drug market is segmented into stage 1, stage 2, stage 3,
- Artificial Tears/Topical Lubricants
- Steroid Eye Drops
Based on treatment, the North America pterygium drug market is segmented into artificial tears/topical lubricants and steroid eye drops.
- Eye Drops
- Eye Ointments
Based on formulation, the North America pterygium drug market is segmented into eye drops, eye ointments, and others.
Mode of Purchase
- Over the Counter (OTC)
Based on the mode of purchase, the North America pterygium drug market is segmented into prescription and over-the-counter (OTC).
Based on population type, the North America pterygium drug market is segmented into geriatric and adults.
- Specialty Clinics
- Home Healthcare
Based on end-user, the North America pterygium drug market is segmented into hospitals, specialty clinics, home healthcare, and others.
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Based on distribution channels, the North America pterygium drug market is segmented into retail pharmacies, hospital pharmacies, and online pharmacies.
North America Pterygium Drug Market Regional Analysis/Insights
The North America pterygium drug market is analyzed, and market size insights and trends are provided by country, disease type, stages, treatment, and formulation, mode of purchase, population type, end-user, and distribution channel as referenced above.
The countries covered in the North America pterygium drug market report are the U.S., Canada, and Mexico.
The North America pterygium drug market is expected to grow due to the presence of big market players in the region and an established healthcare system. The U.S. is expected to dominate the North America pterygium drug market in terms of market share and market revenue. It will continue to flourish its dominance during the forecast period. This is due to the high prevalence of disease in the region.
The country section of the report also provides individual market-impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of North America brands and their challenges faced due to high competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and North America Pterygium Drug Market Share Analysis
The North America pterygium drug market competitive landscape provides details of the competitor. Details include company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, European presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the pterygium drug market.
Some of the major players operating in the North America pterygium drug market are Johnson & Johnson Services, Inc., Novartis AG, Akorn Operating Company LLC, Bausch & Lomb Incorporated, AbbVie Inc., Prestige Consumer Healthcare Inc., Théa Laboratories, Wellona Pharma, Bayer AG, Zydus Group, Amneal Pharmaceuticals LLC, OASIS Medical, Alcon, and Santen Pharmaceutical Co., Ltd. among others.
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by the DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning grids, Market Time Line Analysis, Market Overview and Guide, Company Positioning grids, Company Market Share Analysis, Standards of Measurement, North America Vs Regional, and Vendor Share Analysis. Please request an analyst call in case of further inquiry.